KGJI [KINGOLD JEWELRY] 8-K: (Original Filing)
[]
IDI [IDI] 8-K: (Original Filing)
[IDI, Inc. Reports Second Quarter 2015 Results BOCA RATON, Fla.August 14, 2015IDI, Inc. (NYSE MKT: IDI) On July 23, 2015, the Company completed a $10.0 million registered direct offering with an institutional investor, strengthening its cash position. Key highlights for the second quarter of 2015 include: Rapid development of next-generation data fusion technology, with expected release of idiCORE in] [Item 2.02 Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition. Item 9.01 Item 9.01 99.1 Press Release, dated August 14, 2015]
ACTS [Actions Semiconductor] 6-K: (Original Filing)
[Actions Semiconductor Reports Second Quarter 2015 Results ZHUHAI, China, August 14, 2015 — Actions Semiconductor Co., Ltd. (Nasdaq: ACTS) Commenting on the second quarter results, Dr. Zhenyu Zhou, CEO of Actions Semiconductor said, “Revenue in the second quarter came in at the high end of our expectations and we achieved a meaningful improvement in gross margin. Sales of our multimedia] []
WX [WuXi PharmaTech (Cayman)] 6-K: The Companys board of directors, acting upon the
[The Companys board of directors, acting upon the unanimous recommendation of the special committee formed by the board of directors (the Special Committee), unanimously approved the Merger Agreement and the transactions contemplated by the Merger Agreement, including the Merger, and resolved to recommend that the Companys shareholders authorize and approve the Merger Agreement and the transactions contemplated by the Merger] [EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among NEW WUXI LIFE SCIENCE LIMITED, WUXI MERGER LIMITED and WUXI PHARMATECH (CAYMAN) INC. Dated as of August 14, 2015 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.01 The Merger 2 Section 1.02 Closing; Closing Date 2 Section 1.03 Effective Time 2 Section 1.04 Effects of the Merger 2 Section] [Form 6-K Description Press release dated August 14, 2015 Agreement and Plan of Merger among WuXi PharmaTech (Cayman) Inc., New WuXi Life Science Limited and WuXi Merger Limited, Dated August 14, 2015 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3 6-K 1 d47457d6k.htm FORM 6-K]
CPGI [China Shengda Packaging] 10-Q: (Original Filing)
[FORM 10−Q (Mark One) [X] June 30, 2015 For the quarterly period ended: [ ] For the transition period from ____________to _____________ 001-34997 CHINA SHENGDA PACKAGING GROUP INC. Nevada 26-1559574 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) No. 2 Beitang Road Peoples Republic of China Xiaoshan Economic and Technological Development Zone (86) 571-82838805 _____________________________________________________ Large] [CERTIFICATIONS I, Daliang Teng, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Shengda Packaging Group Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ken He, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Shengda Packaging Group Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. Daliang Teng Chief Executive Officer] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. Ken He Chief Financial Officer (Principal Financial Officer)]
